Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir

Table 1 Baseline characteristics of the study population

Variable	ETV group (n = 30)	TAF group (n = 30)	P value
Age (yr)	46.2 ± 9.8	45.3 ± 10.2	0.69
Sex (male/female)	20/10	19/11	0.77
Body mass index (kg/m2)	24.5 ± 3.2	24.7 ± 3.4	0.82
HBeAg status (positive/negative)	12/18	12/18	> 0.99
Baseline HBV DNA (log 10 IU/mL)	3.7 ± 1.2	3.5 ± 1.1	0.48
Baseline ALT (U/L)	51.3 ± 28.6	49.7 ± 26.4	0.82
Duration of ETV treatment (months)	18.4 ± 6.2	18.7 ± 5.9	0.84

Data are presented as mean ± SD or number. ETV: Entecavir; TAF: Tenofovir alafenamide; HBV: Hepatitis B virus; ALT: Alanine aminotransferase.